



Essential Drugs Company Limited

Statement of Financial Position As at June 30, 2022

Amount in Taka	Notes	June 30, 2022	June 30, 2021
Non current assets:			
Property, plant & equipment	Annexure-A	2,210,133,761	2,262,980,674
Capital work in progress	6.00	7,731,743,112	7,027,011,091
Deferred tax assets	7.00	116,918,631	93,665,415
		<u>10,058,795,504</u>	<u>9,383,657,180</u>
Current assets:			
Inventories	8.00	2,833,717,547	2,161,076,392
Accounts receivable	9.00	371,110,195	185,174,549
Advances, deposits & prepayments	10.00	4,443,243,207	3,641,802,710
Cash and cash equivalents	11.00	5,602,077,951	5,350,028,613
		<u>13,250,148,900</u>	<u>11,338,082,264</u>
Total assets		<u>23,308,944,404</u>	<u>20,721,739,444</u>
Shareholder's equity:			
Share capital	12.00	1,009,248,500	1,009,248,500
General reserve	13.00	3,055,000,000	2,555,000,000
Revaluation reserve	14.00	1,401,306,372	1,410,666,238
Retained earnings		1,343,657,297	845,475,545
		<u>6,809,212,169</u>	<u>5,820,390,283</u>
Long term liabilities:			
Long term loan (Cephalosporin)	15.00	85,000,000	95,000,000
Gratuity payable	17.00	1,410,875,850	1,253,433,650
		<u>1,495,875,850</u>	<u>1,348,433,650</u>
Current liabilities:			
Long term loan (Cephalosporin)-current portion	15.01	850,000	950,000
Long term loan (ADB) -current portion	16.01	397,555,498	360,519,154
Advance against GOB contribution	18.00	6,803,867,969	6,167,995,571
Accounts payable and accrued expenses	19.00	1,144,416,433	1,044,425,284
Bank overdraft	20.00	21,002,690	-
Security deposits	21.00	83,787,392	80,740,447
Advance against sales		3,758,773,644	3,544,603,455
Provision for taxation	22.00	2,793,602,759	2,353,681,600
		<u>15,003,856,385</u>	<u>13,552,915,511</u>
Total equity & liabilities		<u>23,308,944,404</u>	<u>20,721,739,444</u>
Net asset value (NAV) per share	33.00	<u>67.47</u>	<u>57.67</u>


Chairman


Director


Managing Director

Name of Firm: M M Rahman & Co.
Chartered Accountants

Signature of the Auditor: 

Name of the Auditor: Mohammed Forkan Uddin FCA
Managing Partner

DVC : 2212310886AS594791
Dhaka, Date : December 29, 2022

Enrolment No.: 886



Essential Drugs Company Limited

Statement of profit or loss and other comprehensive income
For the year ended June 30, 2022

Amount in Taka	Notes	2021-2022	2020-2021
Sales revenue	23.00	9,020,079,258	6,582,410,128
Cost of goods sold	24.00	(6,570,598,194)	(4,833,317,973)
Gross profit		2,449,481,064	1,749,092,155
Administrative expenses	25.00	(922,424,763)	(807,905,513)
Selling & distribution expenses	26.00	(21,352,115)	(25,497,501)
Operating expenses		(943,776,878)	(833,403,014)
Profit from operation		1,505,704,186	915,689,141
Other income	27.00	89,184,212	70,019,750
Financial expenses	28.00	(6,831,808)	(8,871,129)
Loss on foreign exchange fluctuation		(37,036,344)	(43,116)
Profit before WPPF and welfare funds		1,551,020,246	976,794,646
Workers profit participation fund	29.00	(73,858,107)	(46,514,031)
Profit before tax		1,477,162,139	930,280,615
Current tax expenses		(439,921,159)	(313,749,133)
Deferred tax income/ (expenses)	7.00	23,253,215	27,377,582
Income tax expenses	30.00	(416,667,944)	(286,371,551)
Profit after tax		1,060,494,195	643,909,064
Other Comprehensive Income			
Items that will not be reclassified subsequently to profit or loss			
Deferred Tax Income/(Expense)	7.00	-	-
Total Comprehensive Income for the year		1,060,494,195	643,909,064
Earnings Per Share (EPS)	32.00	10.51	6.38


Chairman


Director


Managing Director

Name of Firm:

M M Rahman & Co.
Chartered Accountants

Signature of the Auditor:



Name of the Auditor:

Mohammed Forkan Uddin FCA
Managing Partner

Enrolment No.:

886

DVC : 2212310886AS594791

Dhaka, Date : December 29, 2022